Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Laurus

Drug and asset intelligence for Laurus with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
5
Catalysts
2
Stage
Development stage unavailable

Recent signals(5)

RegulatoryAugust 18, 2026

FDA Grants AP Status for Metformin Hydrochloride ANDA217631 by Laurus

The FDA has granted approval status (AP) for ANDA217631, a supplemental application for Metformin Hydrochloride submitted by Laurus.

RegulatoryAugust 15, 2026

FDA grants AP status for Metformin Hydrochloride ANDA209882 by Laurus

The FDA has granted Abbreviated Approval (AP) status for ANDA209882, Metformin Hydrochloride application submitted by Laurus.

StrategyJuly 28, 2026

FDA Grants Approval for Valsartan ANDA218897 by Laurus

The FDA has granted approval for ANDA218897, a generic version of Valsartan, submitted by Laurus.

RegulatoryJuly 16, 2026

FDA Grants Approval for Rilpivirine Hydrochloride ANDA219788

The FDA has granted approval for the ANDA219788 application for Rilpivirine Hydrochloride submitted by Laurus.

StrategyJuly 5, 2026

FDA Grants Approval for Valsartan ANDA218897 by Laurus

The FDA has granted an Abbreviated New Drug Application (ANDA) approval for Valsartan submitted by Laurus.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

— Laurus

July 16, 2026 · N/A

Topline Data

— Laurus

July 5, 2026 · N/A

Indications

Diabetes →
Infectious Disease →

Therapeutic areas

Antihypertensive →
Antiretroviral →
Cardiovascular →
Cardiovascular · Antihypertensive →
Diabetes →
Infectious Disease →
Infectious Disease · Antiretroviral →
Oral Hypoglycemic →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.